Valeant Pharmaceuticals Announces New Management Appointments

MONTREAL, Nov. 28, 2012 /CNW/ - Valeant Pharmaceuticals International, Inc. 
(NYSE: VRX and TSX: VRX) announced today that Ryan Weldon and Jason Hanson 
will be named to Valeant's Executive Management Team.  Mr. Weldon will assume 
the role of Executive Vice President/Company Group Chairman where he will lead 
the U.S. Dermatology operations, including prescription dermatology, 
aesthetics and podiatry. Mr. Weldon will be relocating to Arizona where these 
operations will be headquartered.  Mr. Hanson will relocate to New Jersey 
where he will assume the role of Executive Vice President/Company Group 
Chairman and lead certain U.S and international businesses and functions to be 
named later.  In addition, Vince Ippolito will be appointed Senior Vice 
President, General Manager, Aesthetics and Justin Smith will be appointed 
Senior Vice President, General Manager U.S. Rx Dermatology and both will 
report to Ryan Weldon in Scottsdale, AZ.  Mr. Ippolito and Mr. Smith have each 
held various sales and marketing leadership positions at Medicis 
Pharmaceutical Corporation (NYSE: MRX). These changes will be effective upon 
the close of Valeant's acquisition of Medicis, currently anticipated to occur 
on December 11, 2012. 
"The Board of Directors and I are pleased to add such experienced candidates 
to the Valeant management team," said J. Michael Pearson, chairman and chief 
executive officer.  "These individuals have demonstrated exceptional operating 
performance at their respective companies and business units and I believe 
they are the right candidates to continue Valeant's growth and success in the 
future. We expect to be able to announce more management announcements around 
the time of closing." 
Ryan Weldon has served as Vice President & General Manager, Aesthetics since 
December 2011 and Vice President & General Manager, Neurology & Other since 
January 2010. Mr. Weldon joined Valeant in 2008 after working for McKinsey & 
Co. and Johnson & Johnson. 
Jason Hanson has served as Executive Vice President, Chief Operating Officer 
of Medicis Pharmaceutical Corporation since July 2010, and as Executive Vice 
President since 2006. Mr. Hanson joined Medicis in 2006 and was appointed to 
the position of Executive Vice President, General Counsel, and Corporate 
Secretary. From April 2004 to July 2006, Mr. Hanson served as General Counsel 
for GE Healthcare Technologies, a global business specializing in medical 
imaging, information technology and other durable medical equipment and 
services, where he was responsible for the global legal affairs of GE 
Healthcare Technologies and a member of the company's senior management team. 
Vince Ippolito has been with Medicis for ten years where he most recently 
served as Executive Vice President, Sales and Marketing. During his tenure at 
Medicis, he has helped launch more than ten new products, including LOPROX® 
Shampoo, VANOS®, Restylane®, Perlane®, SOLODYN®, ZIANA® and DYSPORT®. 
Prior to joining Medicis, Mr. Ippolito was employed by Novartis AG. 
Justin Smith has been with Medicis for fifteen years where he most recently 
served as Senior Vice President, Marketing for both dermatology and aesthetics 
products.  Most recently, Mr. Smith spearheaded Medicis' access solutions 
strategy and was responsible for launching SOLODYN®.  He also held senior 
positions in sales management. 
About Valeant Pharmaceuticals International, Inc. 
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational 
specialty pharmaceutical company that develops, manufactures and markets a 
broad range of pharmaceutical products primarily in the areas of neurology, 
dermatology and branded generics.  More information about Valeant 
Pharmaceuticals International, Inc. can be found at www.valeant.com. 
Forward-Looking Statements 
This press release may contain forward-looking statements. These 
forward-looking statements relate to, among other things, the closing of the 
Medicis transaction and the future roles of certain management. 
Forward-looking statements can generally be identified by the use of words 
such as "believe," "anticipate," "expect," "estimate," "intend," "continue," 
"plan," "project," "will," "may," "should," "could," "would," "target," 
"potential," and other similar expressions.  In addition, any statements that 
refer to expectations, projections or other characterizations of future events 
or circumstances are forward-looking statements.  Actual results may differ 
materially from those expressed or implied in such statements.  Important 
factors that could cause actual results to differ materially from these 
expectations include, among other things, the satisfaction of customary 
closing conditions with respect to the closing of the Medicis transaction, and 
the risk factors as detailed from time to time in Valeant's reports filed with 
the Securities and Exchange Commission and the Canadian Securities 
Administrators. 
Contact Information:   Laurie W. Little   949-461-6002   
laurie.little@valeant.com 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2012/28/c4178.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: Quebec
NI: HEA MTC BTC 2575 WNEWS  
-0- Nov/28/2012 13:02 GMT